|
||
| |||||||
|
|
Keele, UK,
3rd April 2006 - Cobra Biomanufacturing (AIM: CBF),
the international manufacturer of biopharmaceuticals, today announces the
appointment of Andrew Arrage as Vice President, Business Development for
the Eastern US region. The opening of an East Coast sales office supports
Cobra’s continued expansion of its North American contract manufacturing
business.
In his new position, Andrew will be
responsible for creating strategic business opportunities, and fostering
client relationships for Cobra’s contract manufacturing services. He
brings over 10 years experience in research and business development
within the Life Sciences industry, most recently as Business Development
Executive with Chiltern International, a global full-service CRO.
Prior to Chiltern, he worked at BioReliance
Corporation as Senior Manager of Business Development responsible for
strategic marketing and new business generation for BioReliance’s process
development and cGMP manufacturing services. Andrew has an MBA in New
Venture Analysis from the University of Tennessee and an MS in
Microbiology from Virginia Polytechnic Institute.
David Thatcher, Chief Executive of
Cobra, commented:
“80% of Cobra’s business already originates from the US, this territory constitutes over 70% of the global biopharmaceutical sales. The strengthening of our US footprint will enable Cobra to consolidate its position in the world’s most important pharmaceutical market. I am delighted to welcome Andrew to Cobra Biomanufacturing. His broad, professional experience of sales, marketing and business development in the biotechnology sector will greatly assist Cobra in expansion of its business.”
- ENDS -
About
Cobra Biomanufacturing Plc:
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering recombinant protein, virus, DNA and cellular therapeutics products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines. A range of unique, patented technologies, underpins this revenue generating business.
Cobra floated on the Alternative Investment
Market of the London Stock Exchange in June 2002.
For further information, please
contact:
Cobra Biomanufacturing Plc
Tel: +44 (0) 1782 714 181
David Thatcher, Chief Executive Buchanan Communications
Tel: +44 (0) 207 466 5000
Tim Anderson / Rebecca Skye Dietrich Northbank Communications
Tel: + 44 (0) 1260 296 500
Marc Egelhofer |
| ||||||||||
| ||||||||
